Pharmacological Issues in the Treatment of Tuberculosis
CHARLES A. PELOQUIN,
Corresponding Author
CHARLES A. PELOQUIN
Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado 80206, USA
Schools of Pharmacy and Medicine, University of Colorado, Denver, Colorado 80206, USA
Address for correspondence: Charles A. Peloquin, Pharm.D., Pharmacokinetics Laboratory, Room D-106, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. Voice: 303-398-1427; fax: 303-270-2229; [email protected].Search for more papers by this authorCHARLES A. PELOQUIN,
Corresponding Author
CHARLES A. PELOQUIN
Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado 80206, USA
Schools of Pharmacy and Medicine, University of Colorado, Denver, Colorado 80206, USA
Address for correspondence: Charles A. Peloquin, Pharm.D., Pharmacokinetics Laboratory, Room D-106, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. Voice: 303-398-1427; fax: 303-270-2229; [email protected].Search for more papers by this authorAbstract
Abstract: A thorough review of the clinical trial data combined with new in vitro experimental information may make the optimization of dosages of TB drugs possible. Several factors can affect the selection and dosage of TB drugs including hepatic and renal impairment, pregnancy, duration of disease before treatment, and extent of debilitation. Drug interactions and pharmacodynamics must be considered, and their roles are discussed.
REFERENCES
- 1
Bellissant, E, et al. 1998. Methodological issues in pharmacokinetic-pharmacodynamic modeling.
Clin Pharmacokinet
35: 151–166.
- 2
Peloquin, CA, 1997. Using therapeutic drug monitoring to dose the antimycobacterial drugs.
Clin Chest Med
18: 79–87.
- 3
Lode, H., et al.
1998
Pharmacodynamics of fluoroquinolones.
Clin. Infect. Dis.
27: 33–39.
- 4
Lacy, MK, et al. 1998. The pharmacodynamics of aminoglycosides.
Clin Infect Dis
27: 23–27.
- 5
Turnidge, J.D., et al.
1998
The pharmacodynamics of β-lactams.
Clin. Infect. Dis.
27: 10–22.
- 6
Bartmann, K. 1988. Antituberculosis Drugs. Springer-Verlag. Berlin.
- 7
Goble, M, et al. 1993. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.
N Engl J Med
328: 527–532.
- 8
Berning, S.E. & C.A. Peloquin. 1998. Antimycobacterial agents: cycloserine. In Antimicrobial Chemotherapy. V.L. Yu et al. Eds.: 638–642. Williams and Wilkins. Baltimore, MD.
- 9
Berning, S.E. & C.A. Peloquin. 1998. Antimycobacterial agents: ethionamide. In Antimicrobial Chemotherapy. V.L. Yu et al. Eds.: 650–654. Williams and Wilkins. Baltimore, MD.
- 10
Peloquin, C.A. 1991. Antituberculosis drugs: pharmacokinetics. In Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. L. Heifets, Ed.: 59–88. CRC Press. Boca Raton, FL.
- 11
McEvoy, G.K., Ed. 2001. AHFS Drug Information. American Society of Hospital Pharmacists. Bethesda, MD.
- 12
Malone, RS, et al. 1999. The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.
Chest
116: 984–990.
- 13
Burman, WJ, 1999. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis.
Clin Infect Dis
28: 419–430.
- 14
Narita, M, et al. December 2001. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors.
Clin Infect Dis
32: 515–517.
- 15
Burman, WJ, December 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibiotics.
Clin Pharmacokinet
40: 327–341.
- 16
Barza, M,
M Lauermann. 1978. Why monitor serum levels of gentamicin
Clin Pharmacokinet
3: 202–215.
- 17
McCormack, JP,
PJ Jewesson. 1992. A critical reevaluation of the “therapeutic range” of aminoglycosides.
Clin Infect Dis
14: 320–339.
- 18
Barclay, M.L., et al.
1999. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored
Clin. Pharmacokinet.
36: 89–98.
- 19
Sayers, JFB, 1988. Routine monitoring of serum vancomycin concentrations: the answer lies in the middle.
Clin Pharmocol
7: 18.
- 20
Cantu, TG, et al. 1994. Serum vancomycin concentrations: reappraisal of their clinical value.
Clin Infect Dis
18: 533–543.
- 21
Moellering, RC, 1994. Editorial: monitoring serum vancomycin levels: climbing the mountain because it is there
Clin Infect Dis
18: 544–546.
- 22
Piscitelli, S.C. 2001. The value of drug levels: the plot thickens. Medscape. http://id.medscape.com/Medscape/CNO/2001/RETRO/Story.cfm?story_id=2055
- 23
Peloquin, CA, December 2001. Tuberculosis drug serum levels (letter).
Clin Infect Dis
33: 584–585.
- 24
Mouton, JW, et al. 1999. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.
Antimicrob Agents Chemother
43: 2473–2478.
- 25
Peloquin, CA, et al. 1993. Malabsorption of antimycobacterial medications.
N Engl J Med
329: 1122–1123.
- 26
Patel, KB,
R Belmonte,
HM Crowe. 1995. Drug malabsorption and resistant tuberculosis in HIV-infected patients (letter).
N Engl J Med
332: 336–337.
- 27
Jelliffe, R, 2000. Goal-oriented, model-based drug regimens: setting individualized goals for each patient.
Ther Drug Monit
22: 325–329.
- 28
American Thoracic Society. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children.
Am J Respir Crit Care Med
149: 1359–1374.
